Clinical Trial Update: Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cabazitaxel for brain metastases arising from breast cancer and non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Jevtana (cabazitaxel)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Brain Metastasis, Breast Cancer | Phase 2 | Status: WITHDRAWN